<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Obesity in pregnancy.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Davies GA, Maxwell C, McLeod L, Gagnon R, Basso M, Bos H, Delisle MF, Farine D, Hudon L, Menticoglou S, Mundle W, Murphy-Kaulbeck L, Ouellet A, Pressey T, Roggensack A, Leduc D, Ballerman C, Biringer A, Duperron L, Jones D, Lee LS, Shepherd D, Wilson K, Society of Obstetricians and Gynaecologists of Canada. Obesity in pregnancy. J Obstet Gynaecol Can. 2010 Feb;32(2):165-73. [79 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20181319&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Congenital anomaly, unspecified  (759.9); Exercise counseling  (V65.41); General physical examination  (89.7); Obesity complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication  (649.13); Obesity, unspecified  (278.00)"/><FieldValue Value="MSH: Anesthesia, Obstetrical ; Bariatric Surgery ; Body Mass Index ; Congenital Abnormalities ; Counseling ; Exercise ; Obesity ; Physical Examination ; Pregnancy ; Pregnancy Complications ; Prenatal Care ; Prenatal Diagnosis ; Referral and Consultation ; Risk Assessment ; Thrombolytic Therapy "/><FieldValue Value="MTH: Body mass index procedure ; Congenital Abnormality ; Counseling ; Exercise ; Exercise counseling ; Nutrition education ; Obesity ; physical examination ; Pregnancy ; Pregnancy Complications ; Prenatal care ; Risk Assessment "/><FieldValue Value="PDQ: obesity ; thrombolytic therapy "/><FieldValue Value="SNOMEDCT_US: Antenatal care  (424525001); Congenital malformation  (107656002); Congenital malformation  (21390004); Congenital malformation  (276654001); Congenital malformation  (276655000); Congenital malformation  (385297003); Counseling  (129441002); Counseling  (409063005); Dietary management education, guidance, and counseling  (424753004); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); General appraisal of patient weight  (404639000); Nutrition education  (61310001); Obesity  (414915002); Obesity  (414916001); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pregnancy  (289908002); Risk assessment  (225338004); Thrombolytic therapy  (426347000)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Obesity in pregnancy&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The definition of obesity in pregnancy varies by author and includes women who are 110% to 120% of their ideal body weight or &amp;gt;91 kg (200 lbs) or who have a BMI &amp;gt;30 kg/m&lt;sup&gt;2&lt;/sup&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nutrition" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To review the evidence and provide recommendations for the counselling and management of obese parturients&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Obese women considering pregnancy and obese pregnant women&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Periodic health examinations to encourage healthy weight &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Body mass index (BMI) calculation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Counseling regarding weight gain, nutrition, food choices, exercise and medical complications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for congenital abnormalities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider body mass index when arranging fetal anatomic assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antenatal consultation with anaesthesiologist &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess risk for thromboembolism and consider thromboprophylaxis if appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Counseling and consultation with obesity surgery specialist &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Impact of maternal obesity on the provision of antenatal and intrapartum care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Maternal morbidity and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perinatal morbidity and mortality &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /><FieldValue Value="Searches of Unpublished Data" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Literature was retrieved through searches of Statistics Canada, Medline, and The Cochrane Library on the impact of obesity in pregnancy on antepartum and intrapartum care, maternal morbidity and mortality, obstetrical anaesthesia, and perinatal morbidity and mortality. Results were restricted to systematic reviews, randomized controlled trials/controlled clinical trials, and observational studies. There were no date or language restrictions. Searches were updated on a regular basis and incorporated in the guideline to April 2009. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence Assessment*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;: Evidence obtained from at least one properly randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt;: Evidence from well-designed controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt;: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt;: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt;: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Adapted from the Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The evidence obtained was reviewed and evaluated by the Maternal Fetal Medicine and Clinical Practice Obstetric Committees of the Society of Obstetricians and Gynaecologists of Canada (SOGC) under the leadership of the principal authors, and recommendations were made according to guidelines developed by the Canadian Task Force on Preventive Health Care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classification of Recommendations&amp;dagger;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;. There is good evidence to recommend the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;. There is fair evidence to recommend the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt;. There is fair evidence to recommend against the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;E&lt;/strong&gt;. There is good evidence to recommend against the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;L&lt;/strong&gt;. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This Clinical Practice Guideline has been prepared by the Maternal Fetal Medicine Committee, reviewed by the Clinical Practice Obstetrics Committee, and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The quality of evidence (&lt;strong&gt;I-III&lt;/strong&gt;) and classification of recommendations (&lt;strong&gt;A-E, L&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Periodic health examinations and other appointments for gynaecologic care prior to pregnancy offer ideal opportunities to raise the issue of weight loss before conception. Women should be encouraged to enter pregnancy with a body mass index (BMI) &amp;lt;30 kg/m&lt;sup&gt;2&lt;/sup&gt;, and ideally &amp;lt;25 kg/m&lt;sup&gt;2&lt;/sup&gt;. &lt;strong&gt;(III-B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;BMI should be calculated from pre-pregnancy height and weight. Those with a pre-pregnancy BMI &amp;gt;30 kg/m&lt;sup&gt;2&lt;/sup&gt; are considered obese. This information can be helpful in counselling women about pregnancy risks associated with obesity. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obese pregnant women should receive counselling about weight gain, nutrition, and food choices. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obese women should be advised that they are at risk for medical complications such as cardiac disease, pulmonary disease, gestational hypertension, gestational diabetes, and obstructive sleep apnea. Regular exercise during pregnancy may help to reduce some of these risks. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obese women should be advised that their fetus is at an increased risk of congenital abnormalities, and appropriate screening should be done. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obstetric care providers should take BMI into consideration when arranging for fetal anatomic assessment in the second trimester. Anatomic assessment at 20 to 22 weeks may be a better choice for the obese pregnant patient. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obese pregnant women have an increased risk of Caesarean section, and the success of vaginal birth after Caesarean section is decreased. &lt;strong&gt;(II-2B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antenatal consultation with an anaesthesiologist should be considered to review analgesic options and to ensure a plan is in place should a regional anaesthetic be chosen. &lt;strong&gt;(III-B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk of venous thromboembolism for each obese woman should be evaluated. In some clinical situations, consideration for thromboprophylaxis should be individualized. &lt;strong&gt;(III-B)&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence Assessment*&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt;: Evidence obtained from at least one properly randomized controlled trial&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt;: Evidence from well-designed controlled trials without randomization&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt;: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt;: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt;: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classification of Recommendations&amp;dagger;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;. There is good evidence to recommend the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;. There is fair evidence to recommend the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt;. There is fair evidence to recommend against the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;E&lt;/strong&gt;. There is good evidence to recommend against the clinical preventive action&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;L&lt;/strong&gt;. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Adapted from the Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is specifically stated for each recommendation (see the &quot;Major Recommendations&quot; field). Results were restricted to systematic reviews, randomized controlled trials/controlled clinical trials, and observational studies.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Implementation of the recommendations in this guideline should increase recognition of the issues clinicians need to be aware of when managing obese women in pregnancy, improve communication and consultation amongst the obstetrical care team, and encourage federal and provincial agencies to educate Canadians about the values of entering pregnancy with as healthy a weight as possible.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Davies GA, Maxwell C, McLeod L, Gagnon R, Basso M, Bos H, Delisle MF, Farine D, Hudon L, Menticoglou S, Mundle W, Murphy-Kaulbeck L, Ouellet A, Pressey T, Roggensack A, Leduc D, Ballerman C, Biringer A, Duperron L, Jones D, Lee LS, Shepherd D, Wilson K, Society of Obstetricians and Gynaecologists of Canada. Obesity in pregnancy. J Obstet Gynaecol Can. 2010 Feb;32(2):165-73. [79 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20181319&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Feb" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Society of Obstetricians and Gynaecologists of Canada - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Society of Obstetricians and Gynaecologists of Canada&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Maternal Fetal Medicine Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Principal Authors&lt;/em&gt;: Gregory A.L. Davies, MD, Kingston ON; Cynthia Maxwell, MD, Toronto ON; Lynne McLeod, MD, Halifax NS&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Maternal Fetal Medicine Committee&lt;/em&gt;: Robert Gagnon, MD (&lt;em&gt;Chair&lt;/em&gt;), Montreal QC; Melanie Basso, RN, Vancouver BC; Hayley Bos, MD, London ON; Marie-France Delisle, MD, Vancouver BC; Dan Farine, MD, Toronto ON; Lynda Hudon, MD, Montreal QC; Savas Menticoglou, MD, Winnipeg MB; William Mundle, MD, Windsor ON; Lynn Murphy-Kaulbeck, MD, Allison NB; Annie Ouellet, MD, Sherbrooke QC; Tracy Pressey, MD, Vancouver BC; Anne Roggensack, MD, Calgary AB&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Clinical Practice Obstetrics&lt;/em&gt;: Dean Leduc, MD (&lt;em&gt;Chair&lt;/em&gt;), Ottawa ON; Charlotte Ballerman, MD, Edmonton AB; Anne Biringer, MD, Toronto ON; Louise Duperron, MD, Montreal QC; Donna Jones, MD, Calgary AB; Lily Shek-Yun Lee, MSN, Vancouver BC; Debra Shepherd, MD, Regina SK; Kathleen Wilson, RM, Ilderton ON&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Disclosure statements have been received from all members of the committees.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.sogc.org/guidelines/documents/gui239ECPG1002.pdf&quot; title=&quot;SOGC Web site&quot;&gt;Society of Obstetricians and Gynaecologists of Canada Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Society of Obstetricians and Gynaecologists of Canada, La soci&amp;eacute;t&amp;eacute; des obst&amp;eacute;triciens et gyn&amp;eacute;cologues du Canada (SOGC) 780 promenade Echo Drive Ottawa, ON K1S 5R7 (Canada); Phone: 1-800-561-2416&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on October 7, 2010. The information was verified by the guideline developer on November 15, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
